Coxevac Evropska unija - slovenščina - EMA (European Medicines Agency)

coxevac

ceva santé animale - inaktivirana cepiva coxiella burnetii, sev devet milj - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Startvac Evropska unija - slovenščina - EMA (European Medicines Agency)

startvac

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - imunologija za bovidae - govedo (krave in telice) - za črede imunizacijo zdravih krav in telic, v mlekarice čred z ponavljajoče se vnetje vimena težav, da se zmanjša pojavnost sub-klinično vnetje vimena in pogostnost in resnost kliničnih znakov klinični vnetje vimena, ki jih povzročajo bakterije staphylococcus aureus, coliforms in coagulase-negativni stafilokoki. celotna imunizacijska shema povzroči imuniteto od približno 13 dni po prvi injekciji do približno 78 dni po tretji injekciji (kar ustreza 130 dni po porodu).

Ubac Evropska unija - slovenščina - EMA (European Medicines Agency)

ubac

laboratorios hipra, s.a. - lipoteichoic kisline iz biofilma oprijem del streptococcus uberis, sev 5616 - imunologija za bovidae - govedo - za aktivno imunizacijo zdravih krav in telic, da zmanjša pojavnost kliničnih intramammary okužb, ki jih povzroča streptococcus uberis, da se zmanjša telesni število celic v streptococcus uberis pozitivno četrtletju vzorcev mleka in zmanjšanje proizvodnje mleka izgube, ki jih povzroča streptococcus uberis intramammary okužb.